According to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI) (emphasis in original):
|
|
- Russell Simmons
- 5 years ago
- Views:
Transcription
1 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD TRANSMITTED BY FACSIMILE Bhavana Desai Senior Director, Advertising and Promotional Compliance 2525 Dupont Drive AND-1M P.O. Box Irvine, CA RE: NDA # Latisse TM (bimatoprost ophthalmic solution) 0.03% MACMIS #17844 Dear Ms. Desai, As part of its routine monitoring and surveillance program, the Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the FAQs 1 and About Safety 2 pages of a consumer website and a Launch display timeline (timeline) (APC36ON09) for Latisse TM (bimatoprost ophthalmic solution) 0.03% (Latisse) submitted by (Allergan) under cover of Form FDA These promotional materials are misleading because they omit and minimize risks associated with Latisse. Thus, the website and timeline misbrand Latisse in violation of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 352(a) & (n); 321(n), and FDA implementing regulations. See 21 CFR 202.1(e)(3)(i); (e)(5) & (e)(7)(viii). Background According to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI) (emphasis in original): LATISSE TM (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. Latisse is associated with several risks. The WARNINGS AND PRECAUTIONS section of the PI states (in pertinent part; emphasis in original): Iris Pigmentation Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN ) was instilled directly onto the eye.... [P]atients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent. 1 Latisse FAQs webpage, at (last accessed June 19, 2009). 2 Latisse About Safety webpage, at (last accessed June 19, 2009).
2 Bhavana Desai Page Lid Pigmentation Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.... Hair Growth Outside the Treatment Area There is the potential for hair growth to occur in areas where LATISSE TM solution comes in repeated contact with the skin surface. It is important to apply LATISSE TM only to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying sterile applicators, and to carefully blot any excess LATISSE TM from the eyelid margin to avoid it running onto the cheek or other skin areas.... Intraocular Inflammation LATISSE TM solution should be used with caution in patients with active intraocular inflammation... because the inflammation may be exacerbated..... Contamination of LATISSE TM or Applicators The LATISSE TM bottle must be kept intact during use. It is important to use LATISSE TM solution as instructed, by placing one drop on the single-use-per eye applicator. The bottle tip should not be allowed to contact any other surface since it could become contaminated. The accompanying sterile applicators should only be used on one eye and then discarded since reuse of applicators increases the potential for contamination and infections. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.... Use with Contact Lenses LATISSE TM contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.... The PATIENT COUNSELING INFORMATION section of the PI states (in pertinent part; emphasis in original): Potential for Unexpected Hair Growth or Eyelash Changes Patients should be informed of the possibility of hair growth occurring outside of the target treatment area if LATISSE TM repeatedly touches the same area of skin outside the treatment area. They should also be informed of the possibility of disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth.... The DOSAGE AND ADMINISTRATION section of the PI states (in pertinent part; emphasis in original):... Do not apply to the lower eyelash line (see WARNINGS AND PRECAUTIONS, 5.3 [Lid Pigmentation]....)
3 Bhavana Desai Page 3 Furthermore, the Latisse Patient Package Insert (PPI) states (in pertinent part; emphasis in original): Are there any special warnings associated with LATISSE TM use? LATISSE TM solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes.... DO NOT APPLY to the lower eyelid.... In addition, the Latisse PPI states (in pertinent part; emphasis in original): What are the possible side effects of LATISSE TM?... If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your physician s advice concerning the continued use of LATISSE TM solution. The most frequently reported adverse events associated with Latisse are eye pruritis, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. Omission and Minimization of Risk Information Promotional materials are misleading it they fail to reveal material facts in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested by the materials. Promotional materials are also misleading if they fail to present risk information associated with a drug with a prominence and readability reasonably comparable with the claims of effectiveness related to the drug. Launch Display Timeline The Launch Display Timeline presents an exhibit of the Evolution of Lash Enhancers starting in 4000 B.C., where darkening powders [were] used to embellish the eye, and leading up to the present day with the arrival of Latisse. Specifically, at the end of the timeline describing the various eyelash enhancers through time, a large, colorful logo for Latisse is presented in conjunction with the large bolded headline, 2009, LATISSE TM Arrives, and other efficacy claims for Latisse such as, LATISSE TM introduces an historic innovation in eyelash enhancement. LATISSE TM is the first and only prescription treatment approved by the FDA for hypotrichosis of the eyelashes (inadequate or not enough lashes) that is used to grow eyelashes, making them longer, fuller and darker.... In stark contrast to this efficacy presentation, the only risk information that is presented for Latisse is included on a small placard to the lower right of the timeline exhibit. As such, this display fails to present risk information with a prominence and readability reasonably comparable with the presentation of information relating to the effectiveness of the drug.
4 Bhavana Desai Page 4 Furthermore, the risk information that is presented on the placard omits important risks associated with Latisse. In particular, the risk disclosure fails to convey the risk of hair growth outside of the treatment area if Latisse comes in repeated contact with the skin surface. In addition, although we note that the placard claims, LATISSE TM solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes, this claim fails to state that Latisse should not be applied to the lower eyelash line, or lower eyelid, as stated in the Latisse PI and PPI, respectively. We note the statements, Full prescribing information is available at and Also available here. However, these statements do not mitigate this misleading omission and minimization of risk information. The overall effect of this presentation minimizes the risks associated with Latisse and misleadingly suggests that Latisse is safer than has been demonstrated. FAQs and About Safety Webpages Similarly, the FAQs and About Safety webpages are misleading because they omit and minimize risks associated with Latisse treatment, thus implying that Latisse is safer than has been demonstrated by substantial evidence or substantial clinical experience. For example, the webpages omit important risks associated with Latisse, including the risk of bacterial keratitis from contamination of Latisse or the applicators, and the risk of use with contact lenses. In addition, the webpages do not mention the potential for disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and the direction of eyelash growth. Moreover, the body of the About Safety webpage fails to communicate the potential for excess hair growth outside of the treatment area. In addition, the risk presentations that are included on the webpages further minimize the risks associated with Latisse. For example, the webpages make the following claims (emphasis added): Eye redness may occur immediately after use, but should usually last only for a short period of time. Eye redness alone is not an allergic reaction or inflammation, and doesn t mean that your eyes are being harmed... ( FAQs webpage); Eye itching may occur immediately after use, but should usually last only for a short period of time (one to two weeks during initial use). Eye itching alone is not an allergic reaction, and doesn t mean that your eyes are being harmed. Consult your doctor if the itching persists or you notice other symptoms as well ( FAQs webpage); and The most common side effects after using LATISSE solution are an itching sensation in the eyes and/or eye redness, which were reported in approximately 4% of patients. These may occur immediately after use, but should usually last only for a short period of time. Eye itching and eye redness are not allergic reactions, and do not mean that your eyes are being harmed... ( About Safety webpage).
5 Bhavana Desai Page 5 These claims minimize the risks associated with Latisse because they misleadingly suggest that eye itching and redness are not associated with allergic reactions of the eyes related to Latisse treatment. However, according to Latisse s PI, allergic conjunctivitis is an adverse reaction reported with bimatoprost ophthalmic solution, which is the same active ingredient that is used in Latisse. Moreover, eye redness and itching, which are frequent symptoms of an allergic reaction, usually resolve only after discontinuation of the drug. These claims are also concerning because patients are highly unlikely to be able to differentiate between eye redness associated with conjunctival hyperemia, allergic reaction, or inflammation without the advice of a healthcare provider. We note the statement, Consult your doctor if the itching persists or you notice other symptoms as well, in the second bulleted claims; however this does not mitigate the misleading impression that patients with eye itching or redness are not having an allergic reaction and should not be concerned. Furthermore, the FAQs and About Safety webpages contain the following statement (emphasis added): Increased brown iris pigmentation has occurred when similar medications were instilled directly into the eye to treat elevated intraocular pressure/glaucoma. This statement misleadingly suggests that only similar medications have been associated with the risk of increased iris pigmentation. However, brown iris pigmentation has been reported with bimatoprost ophthalmic solution, which is the same active ingredient present in Latisse. By omitting this material information and suggesting this side effect has only occurred with similar medications, this claim minimizes the risk of increased iris pigmentation. In addition, the About Safety webpage presents the following question and answer presentation (emphasis in original): Is LATISSE safe? LATISSE is an FDA-approved prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Hypotrichosis is another name for having inadequate or not enough eyelashes. The FDA reviewed clinical study results to verify the identity, potency, purity and stability of the ingredients, and demonstrated that the product is safe and effective for its intended use if used as prescribed. The answer to the question, Is LATISSE safe? fails to include any mention of the fact that the use of Latisse is associated with side effects, or to mention any of these side effects. In addition, the answer implies that Latisse is especially safe because the FDA has verified the identity, potency, purity, and stability of the ingredients in Latisse. This presentation thus significantly minimizes the risks of the drug. Furthermore, the FAQs webpage contains the following presentation: Why do the directions say to only apply LATISSE solution to the base of the upper eyelashes?
6 Bhavana Desai Page 6 A clinical trial of LATISSE was conducted on patients who applied the product to the base of their upper lashes only. Applied nightly, the transfer of LATISSE solution from the upper to lower eyelid may occur naturally because the eyelids are closed and the eyelashes touch each other.... This presentation is misleading because the answer provided above omits material contextual information regarding the risk of excess hair growth outside of the treatment area if Latisse comes in continued contact with the skin area; it is because of this risk that the directions say to only apply Latisse to the base of the upper eyelashes. The above presentation also fails to disclose that Latisse should not be applied to the lower eyelash line, or lower eyelid, as stated in the Latisse PI and PPI, respectively. Conclusion and Requested Action For the reasons discussed above, the timeline and webpages misbrand Latisse in violation of the Act, 21 U.S.C. 352(a) & 352(n); 321(n), and FDA implementing regulations. See 21 CFR 202.1(e)(3)(i); (e)(5) & (e)(7)(viii). DDMAC requests that Allergan immediately cease the dissemination of violative promotional materials for Latisse such as those described above. Please submit a written response to this letter on or before September 24, 2009, stating whether you intend to comply with this request, listing all promotional materials (with the 2253 submission date) in use for Latisse as of the date of this letter, identifying which of these materials contain violations such as those described above, and explaining your plan for discontinuing use of such violative materials. Please direct your response to me at the Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications, 5901-B Ammendale Road, Beltsville, MD , facsimile at In all future correspondence regarding this matter, please refer to MACMIS # in addition to the NDA number. We remind you that only written communications are considered official. The violations discussed in this letter do not necessarily constitute an exhaustive list. It is your responsibility to ensure that your promotional materials for Latisse comply with each applicable requirement of the Act and FDA implementing regulations. Sincerely, {See appended electronic signature page} Sharon M. Watson, PharmD LCDR, USPHS Regulatory Review Officer Division of Drug Marketing, Advertising, and Communications
7 Application Type/Number Submission Type/Number Submitter Name Product Name NDA ORIG-1 ALLERGAN INC BIMATOPROST SOLUTION 0.03% This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature /s/ SHARON M WATSON 09/10/2009
Below is the indication and summary of the most serious and most common risks associated with the use of Natroba. 1
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Kerry W. Mettert Director, Quality and Regulatory 11550 North Meridian
More informationDo not apply to the lower eyelash line [see Warnings and Precautions (5.3, 5.4) and Patient Counseling Information (17.1)].
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE LATISSE (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness
More informationRE: NDA Tri-Luma Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) MACMIS #17768 WARNING LETTER
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Francois Fournier, President and CEO 14501 North Freeway Fort Worth,
More informationNEWS RELEASE. CONTACTS: Investors: Lisa DeFrancesco (862) Media: Mark Marmur (862) Ember Garrett (714)
NEWS RELEASE CONTACTS: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 Ember Garrett (714) 246-3525 JUVÉDERM VOLBELLA XC APPROVED BY U.S. FDA FOR USE IN LIPS AND PERIORAL RHYTIDS
More informationPENTAMYCETIN is an antibiotic that: Stops the growth of bacteria Kills bacteria
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Read this carefully before you start taking PENTAMYCETIN each time you get a refill. This leaflet is a summary and will
More informationJaychem Industries Ltd 9/4/15
Jaychem Industries Ltd 9/4/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 VIA UPS RETURN RECEIPT REQUESTED Warning Letter WL: 320-15-16
More informationBIMATOPROST- bimatoprost solution/ drops Sandoz Inc
BIMATOPROST- bimatoprost solution/ drops Sandoz Inc ---------- HIGHLIGHT S OF PRESCRIBING INFORMAT ION These highlights do not include all the information needed to use BIMATOPROST OPHTHALMIC SOLUTION
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. TRAVATAN Z Travoprost Ophthalmic Solution
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr TRAVATAN Z Travoprost Ophthalmic Solution Read this carefully before you start taking TRAVATAN Z and each time you
More informationH 7915 S T A T E O F R H O D E I S L A N D
LC00 0 -- H S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 0 A N A C T RELATING TO FOOD AND DRUGS - RHODE ISLAND FOOD, DRUGS, AND COSMETICS ACT Introduced By: Representatives
More informationNUTRALUXE MD TRAINING MANUAL: NUTRALUXE EYES BY NUTRALUXE MD TOPICS BASIC ITEM INFORMATION PRODUCT SUMMARY ABOUT WHY BENEFITS WHAT TO EXPECT
NUTRALUXE MD TRAINING MANUAL: NUTRALUXE EYES BY NUTRALUXE MD TOPICS BASIC ITEM INFORMATION PRODUCT SUMMARY ABOUT WHY BENEFITS WHAT TO EXPECT INSTRUCTIONS OF USE PRODUCT PICTURES FREQUENTY ASKED QUESTIONS
More informationPearl Fusion Technique
Pearl Fusion Technique Combined Treatment Advanced Technique General Considerations The Pearl Fusion Technique is an advanced procedure intended for operators with previous knowledge and experience with
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Keystone Laboratories
More informationSELECT 1 DAY CONTACT LENS
PACKAGE INSERT Select 1 Day (somofilcon A) SYMBOLS KEY Soft (hydrophilic) Contact Lenses for Daily Wear Single Use Only The following symbols may appear on the label or carton. SYMBOL LOT! STERILE DEFINITION
More informationREGISTRATIONS APPROVALS LISTINGS PREPARING FOR US FDA INSPECTIONS 483 RESPONSES
REGISTRATIONS APPROVALS LISTINGS PREPARING FOR US FDA INSPECTIONS 483 RESPONSES FORMULATIONS & API s MEDICAL DEVICES FOOD FEED DIETARY SUPPLIMENTS COSMETICS United States Agent Services Under the Code
More informationCOSMETICS EUROPE: COMMISSION RECOMMENDATION ON THE EFFICACY OF SUNSCREEN PRODUCTS AND THE CLAIMS MADE RELATING THERETO
COSMETICS EUROPE: COMMISSION RECOMMENDATION ON THE EFFICACY OF SUNSCREEN PRODUCTS AND THE CLAIMS MADE RELATING THERETO SEPTEMBER 2006 26.9.2006 Official Journal of the European Union L 265/39 COMMISSION
More informationHOW TO USE. and make the most out of your CTCL treatment
HOW TO USE and make the most out of your CTCL treatment TARGRETIN Gel should not be used by women who are pregnant, believe they may be pregnant, or are planning to become pregnant. Please see Important
More informationFor external use only Havana St. Denver, Colorado 80239
1. PRODUCT AND COMPANY IDENTIFICATION Product Name Neoteric Diabetic Shampoo Product Type Finished Product Recommended use Personal Beauty Care For external use only. Manufacturer Neoteric Cosmetics, Inc.
More informationA novel daily moisturizing cream for effective management of mild to moderate Atopic Dermatitis in infants and children
TM Weber PhD 1, F Samarin MD 3, M Babcock MD 2, A Filbry PhD 4, C Arrowitz 1, F Rippke MD 4 1 Beiersdorf Inc., Wilton CT, USA 2 Mountaintop Dermatology, Colorado Springs CO, USA 3 Colorado Springs Dermatology
More informationPre Treatment Advice and Procedures
Pre Treatment Advice and Procedures 1. Since delicate skin or sensitive areas may swell slightly, or redden, it is advised not to make social plans for the same day. Lip liner may appear crusty for up
More information(Injection of collagen, hyaluronic acid or other filler materials) INFORMED CONSENT FOR DERMAL FILLER
INFORMED CONSENT FOR DERMAL FILLER (Injection of collagen, hyaluronic acid or other filler materials) INTRODUCTION Dermal fillers are injected just under the skin s surface in order to temporarily correct
More informationProcedure/ Care Plan for Domiciliary Care Workers/ Support Workers - Application of Prescribed Creams/ Ointments/ Lotions (Adult)
Application of Prescribed Creams/ Ointments/ Lotions (Adult) CLINICAL GUIDELINES ID TAG Medicines Management Specific Title: Procedure: Application of prescribed Creams/ Ointments/ Lotions (Adult) Author:
More informationCase 4:18-cv PJH Document 25 Filed 08/14/18 Page 1 of 88
Case :-cv-0-pjh Document Filed 0// Page of 0 0 Jeffrey Lewis (Bar No. ) KELLER ROHRBACK L.L.P. 00 Lakeside Drive, Suite 000 Oakland, CA (0) -00, Fax (0) -0 jlewis@kellerrohrback.com Juli Farris (Bar No.
More informationCase 4:18-cv Document 1 Filed 04/13/18 Page 1 of 41
Case :-cv-0 Document Filed 0// Page of Jeffrey Lewis (Bar No. ) KELLER ROHRBACK L.L.P. 00 Lakeside Drive, Suite 00 Oakland, CA () -00; Fax: () -0 jlewis@kellerrohrback.com Juli Farris (Bar No. ) KELLER
More information. DEFY LINES. along the sides of your nose and mouth ON YOUR FACE.
. DEFY LINES. ( PARENTHESES HAVE NO PLACE) ON YOUR FACE. n Instantly smooths away the deeper lines along the sides of your nose and mouth n Provides natural-looking results Actual patient. Results may
More informationPackage leaflet: Information for the user. ZORAC 0.05% gel ZORAC 0.1% gel. Tazarotene
Package leaflet: Information for the user ZORAC 0.05% gel ZORAC 0.1% gel Tazarotene Read all of this leaflet carefully before you start using this medicine because it contains important information for
More informationEVERYONE WILL NOTICE. No One Will Know.
THE WORLD S #1 SELLING DERMAL FILLER COLLECTION EVERYONE WILL NOTICE. No One Will Know. Get the natural-looking, long-lasting results you desire. Ask your aesthetic specialist about JUVÉDERM today. Actual
More informationInformed Consent for Dermal Filler
Informed Consent for Dermal Filler NAME: DATE OF BIRTHG: ADDRESS: CELL PHONE: EMAIL: www.medicaleyecenter.com Please initial all of the following sections confirming that you have read and understand each
More informationKoC03of. 510(k) SUMMARY. Lexington International, LLC LaserComb. Submitter's Contact Information. Name: David Michaels, Managing Director JAN
KoC03of 510(k) SUMMARY Lexington International, LLC LaserComb Submitter's Contact Information Name: David Michaels, Managing Director JAN 1 8 2667 Address: Lexington International, LLC 2650 North Military
More informationThe Natrelle ConfidencePlus Warranty Program
WARRANTY The Natrelle ConfidencePlus Warranty Program Offering you more coverage for your peace of mind Nikki Natrelle INSPIRA Responsive Style SRF-415 Individual results may vary. Please see inside for
More informationSAFETY DATA SHEET Conforms with OSHA Hazard Communication Standard (CFR ) HazCom 2012
SECTION 1 - IDENTIFICATION Product Identifier Product Name: Surgical Instrument Stain Remover Product Code: 3-740 Recommended Use of the Chemical and Restrictions on Use Recommended Use: Used for removing
More informationWhen your eyes feel dry, burning or itchy, there s a range of solutions:
When your eyes feel dry, burning or itchy, there s a range of solutions: The complete range of preservative-free eye drops. PATIENT INFORMATION The feeling of dry eyes is very common and can be quite debilitating
More informationCOSMETICS EUROPE: N 24B HAIR DYE LABELLING - INFORMATION FOR PROFESSIONALS
COSMETICS EUROPE: N 24B HAIR DYE LABELLING - INFORMATION FOR PROFESSIONALS 2011 RECOMMENDATION N 24b LABELLING INFORMATION AND WARNINGS FOR PROFESSIONAL HAIR COLOURING PRODUCTS FINAL 2011 Note: This recommendation
More informationWe understand that a competitor has raised the following issues which we will address in this letter.
March 01, 2010 Dear Customer, Thank you for your recent inquiry into PURELL Waterless Surgical Scrub. PURELL is an effective surgical scrub formulation that meets the requirements of the surgical scrub
More informationUNIVERSITY OF HAWAII Community Colleges ENVIRONMENTAL HEALTH AND SAFETY OFFICE HAZARD COMMUNICATION PROGRAM
UNIVERSITY OF HAWAII Community Colleges ENVIRONMENTAL HEALTH AND SAFETY OFFICE HAZARD COMMUNICATION PROGRAM Revised January 2011 TABLE OF CONTENTS 1.0 INTRODUCTION 2.0 PROGRAM ADMINISTRATION 3.0 AN OVERVIEW
More informationEASTERN KENTUCKY UNIVERSITY HAZARD COMMUNICATION PROGRAM SUMMARY COMPLIANCE MANUAL. Table of Contents
EASTERN KENTUCKY UNIVERSITY HAZARD COMMUNICATION PROGRAM SUMMARY COMPLIANCE MANUAL Table of Contents I. OVERVIEW OF THE HAZARD COMMUNICATION STANDARD A. Background and Scope.................................
More informationDesigned for. What kind of fullness do you desire? Natrelle Gel breast implants are. increased fullness, classic fullness, and shaped fullness.
What kind of fullness do you desire? Natrelle Classic Style 15 Individual results may vary. Natrelle 410 Style FM Individual results may vary. Natrelle INSPIRA Style SRM-310 Individual results may vary.
More informationRegulation of Cosmetics in Korea. Chin SooYoung Consulting
Regulation of Cosmetics in Korea Chin SooYoung Consulting Classification in Korea Regulatory classification Quasi-drug (QD) Category Feminine Care Hair Care Oral Care Vitamins Anti-perspirant Anti septic
More informationChemical Peels Corporate Medical Policy
Chemical Peels Corporate Medical Policy File Name: Chemical Peels File Code: UM.SURG.13 Origination: 08/2016 Last Review: 10/2018 Next Review: 10/2019 Effective Date: 01/01/2019 Description/Summary A chemical
More informationEyeLocc. Eyelid Occlusion Dressings
EyeLocc Eyelid Occlusion Dressings EyeLocc Eyelid Occlusion Dressings About EyeLocc The EyeLocc is a unique dressing specifically designed for eyelid occlusion during general anaesthesia. It provides quick,
More informationREFORM THE QUASI-DRUG APPROVAL SYSTEM
REFORM THE QUASI-DRUG APPROVAL SYSTEM Reform the Quasi-Drug Approval System YEARLY STATUS REPORT: Slight Progress In October 2016 and September 2017, MHLW s Evaluation and Licensing Division issued a notification
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 28-May-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product Name Product Type Recommended Use Uses advised against 95878674_NA MaxFactorColourX-PertWaterproofEyeliner
More informationMicropigmentation (Semi-Permanent Makeup) Informed Consent
Micropigmentation (Semi-Permanent Makeup) Informed Consent The nature and method of the proposed semi-permanent makeup (cosmetic tattoo) procedure has been explained to me as having the usual risks inherent
More informationam pm PURE Anti-Acne Deep Cleanser PURE
PURE A1 PURE Anti-Acne Deep Cleanser Apply a small amount to fingers, lather with warm water, gently wash face, neck, décolletage and/or back areas to cleanse oils, dirt, and makeup. For best results use
More informationWhere Science Meets Skin Care
Where Science Meets Skin Care The AQ Mission: AQ Skin Solutions is dedicated to producing premium, effective skin and hair care products to professionals in the medical field and consumers around the world.
More informationCLARITI 1 DAY CONTACT LENS
PACKAGE INSERT Clariti 1 Day (somofilcon A) Clariti 1 Day Toric (somofilcon A) Clariti 1 Day Multifocal (somofilcon A) Clariti 1 Day Multifocal Toric (Somofilcon A) SYMBOLS KEY Soft (hydrophilic) Contact
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 09-Oct-2013 Version 1 1. PRODUCT AND COMPANY IDENTIFICATION Product ID: Product Name Product Type Recommended use Uses advised against Synonyms Manufacturer E-mail
More informationSAFETY DATA SHEET Refresh AntiBac Foam (BAC)
SAFETY DATA SHEET Refresh AntiBac Foam (BAC) 1. Identification Product identifier Product name Internal identification Refresh AntiBac Foam 26111/0000 Recommended use of the chemical and restrictions on
More informationProducts to recommend for the TREATMENT of Dry Eyes
Products to recommend for the TREATMENT of Dry Eyes Active ingredient: Polyethylene Glycol 400 0.4% Propylene Glycol 0.3% Systane Lubricating Eye drops & Unit dose vials For the temporary relief of burning
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 12-Dec-2013 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product name Product type Recommended use Uses advised against Synonyms Manufacturer E-mail
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET Issuing Date: 25-Nov-2013 Version 1 1. Product and Company Information Product ID: Product name Product Type Recommended Use Uses advised against Synonyms Manufacturer E-mail
More informationGermanna Community College Policy 70210: Hazard Communication Plan
1. Purpose Germanna Community College Policy 70210: Hazard Communication Plan 1.1. To establish guidelines and policies to make Germanna Community College employees aware of chemical hazards to which they
More informationScabies. Dr. Ghassan Salah
Scabies Dr. Ghassan Salah Scabies Scabies is a skin infestation caused by a mite Causes: The female scabies mite (Sarcoptes scabei ) burrows through the stratum corneum of the skin and lays its eggs just
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 24-Apr-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product name Product type Recommended use Uses advised against Synonyms Manufacturer E-mail
More informationPatient Information Leaflet. Dermal Filler
Patient Information Leaflet Dermal Filler When considering treatment with dermal fillers we want you to have a safe treatment. Some risks are unavoidable and out of your control. The following information
More informationStrengthening the Compliance to the Malaysia Cosmetic Regulation & Requirements
Strengthening the Compliance to the Malaysia Cosmetic Regulation & Requirements 1 Presentation Outline Introduction Post Market Surveillance : Challenges New updates : directives, circular & guidelines
More informationHOW TO USE. and make the most out of your cutaneous T-cell lymphoma (CTCL) treatment
HOW TO USE and make the most out of your cutaneous T-cell lymphoma (CTCL) treatment TARGRETIN gel should not be used by women who are pregnant, believe they may be pregnant, or are planning to become pregnant.
More informationTopi-CLICK 140 Specifications
126mm 140 ml Topi-CLICK 140 Specifications Topi-CLICK 140: 140 ml, 0.50 ml per CLICK DESCRIPTION: The NEW Topi-CLICK 140 is an intelligently designed topical dosing device that overcomes the various limitations
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 10-Oct-2012 Version 1 Product ID: 92297934 1. PRODUCT AND COMPANY IDENTIFICATION Product Name Product Type Recommended use Uses advised against Synonyms Manufacturer
More informationREFORM THE QUASI-DRUG APPROVAL SYSTEM
REFORM THE QUASI-DRUG APPROVAL SYSTEM Reform the Quasi-Drug Approval System YEARLY STATUS REPORT: Progress The Ministry of Health, Labour and Welfare (MHLW) released a model template for ordinary quasi-drug
More informationCLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE National Drug Code Directory
68682-132-50 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA)
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 15-Aug-2012 Version 1 Product ID: 98910402 1. PRODUCT AND COMPANY IDENTIFICATION Product Name Product Type Recommended use Uses advised against Synonyms Manufacturer
More informationA GUIDE TO STARTING STELARA
A GUIDE TO STARTING STELARA 1 PRESCRIBE STELARA FOR CROHN S DISEASE 2 3 VERIFY PATIENT INSURANCE BENEFITS START STELARA WITH IV INDUCTION AND SUBQ MAINTENANCE For the treatment of adults with moderately
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 12-Jun-2013 Revision Date: 12-Jun-2013 Version 1 Product ID: 96206077 1. PRODUCT AND COMPANY IDENTIFICATION Product name Product Type Recommended use Uses advised
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 04-Sep-2013 Version 1 Product ID: 15812010 1. PRODUCT AND COMPANY IDENTIFICATION Product Name Product Type Recommended use Uses advised against Synonyms COVERGIRLReady,SetGorgeous
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 15-Jan-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product name Product type Recommended use Uses advised against 96634601_NA GUCCI FACE Golden
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 31-Mar-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product name Product type Recommended use Uses advised against 96765753_NA COVER GIRL; Colorlicious
More informationSeptember 23, Dear Dr. Hamburg:
September 23, 2011 Dr. Margaret A. Hamburg, M.D. Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993-0002 Dear Dr. Hamburg: On behalf of the
More informationPermanent Makeup Before & Aftercare Instructions. Permanent Makeup by Michelle Louise
Permanent Makeup by Michelle Louise Permanent Makeup Before & Aftercare Instructions IMPORTANT INFORMATION This document contains important information. Please read it carefully. www.michelle-lousie.com
More informationINFORMED CONSENT Juvederm INJECTION
INSTRUCTIONS This is an informed-consent document which has been prepared to help Dr. Jennifer Geoghegan inform you concerning Juvederm (Non-Animal Stabilized Hyaluronic Acid, Allergan Aesthetics) tissue
More informationProduct Name: Acne Medication Benzoyl Peroxide 10% Lotion Synonyms: None. Emergency telephone number: CHEMTREC
1. Product and Company Identification Product Name: Acne Medication Benzoyl Peroxide 10% Lotion Synonyms: None Recommended Use: Uses Advised Against: No information available Supplier information: Garcoa
More informationNew Mexico Institute of Mining & Technology. Hazard Communication Policy
New Mexico Institute of Mining & Technology Hazard Communication Policy BASIS: The OSHA Hazard Communication Standard establishes uniform requirements to ensure that the hazards of all chemicals used at
More informationFor Acne Vulgaris, A Topical Gel Treatment For Dermatologic Use
For Acne Vulgaris, A Topical Gel Treatment For Dermatologic Use ERYGEL (Erythromycin) Topical Gel USP, 2% Please see Important Safety Information on back page and accompanying Full Prescribing Information.
More informationINFORMED CONSENT SOFT TISSUE FILLER INJECTION
INSTRUCTIONS This informed-consent document has been prepared to help inform you about Hylaform (animal-origin, stabilized hyaluronic acid, INAMED) tissue-filler injection therapy Restylane (Non-Animal
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 29-Apr-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product Name Product Type Recommended Use Uses advised against 96505618_NA CG Advanced Radiance
More informationPackage leaflet: Information for the patient SAFLUTAN 15 micrograms/ml Eye drops, solution in single dose-container. Tafluprost
Package leaflet: Information for the patient SAFLUTAN 15 micrograms/ml Eye drops, solution in single dose-container Tafluprost Read all of this leaflet carefully before you start using this medicine because
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: no data available Version 1 1. PRODUCT AND COMPANY IDENTIFICATION Product ID: Product Name Product Type Recommended use Uses advised against 95575935_NA COVERGIRL
More informationRevisions Made? Yes No_X_
Policy Title: Hazard Communication Information to Employees Policy #: FA-CPS-004 Responsible Office: Campus Public Safety Responsible Vice President for Finance and Administrator: Administration Date Reviewed:
More informationSAFETY DATA SHEET WINSOR & NEWTON LIQUIN LIGHT GEL
REVISION DATE: 03/06/2011 SAFETY DATA SHEET WINSOR & NEWTON LIQUIN LIGHT GEL 1 IDENTIFICATION OF THE SUBSTANCE/ PREPARATION AND COMPANY UNDERTAKING PRODUCT NAME APPLICATION SUPPLIER WINSOR & NEWTON LIQUIN
More informationPress Kit: Primary Messaging
Press Kit: Primary Messaging The following points outline three key differentiators of Revanesse Versa TM. Using these points as a guideline and basis for content creation will help ensure product claims
More informationINJECTABLES. Botox Cosmetic Page 1 of 7. FAQ s
290 Country Club Drive, Stockbridge, Georgia 30281 770.506.9123 www.schillingmedicalspa.com FAQ s INJECTABLES Botox Cosmetic WHAT EXACTLY IS BOTOX COSMETIC? BOTOX Cosmetic is a purified protein produced
More informationMidlands Laser Clinic
Midlands Laser Clinic Laser Tattoo Removal Useful Information Tattoo Removal using the QX MAX "Q" Switched LASER should only be undertaken by fully trained and qualified personnel. Please ask to see the
More informationPesticide Labeling: Signal Words 1
P-100 1 Frederick M. Fishel 2 This document interprets signal words seen on pesticide labels and discusses the toxicity criteria used in determining the appropriate signal word for the pesticide. Examples
More informationMarch 2013 ==================== Jason B. Lichten, M.D., FACS
March 2013 Jason B. Lichten, M.D., FACS I hope you're giving your complexion lots of TLC before and after your treatments here at our office. A key element in that care is using excellent topical lotions.
More informationPATIENT INFORMATION LEAFLET PUVA TREATMENT. using. Puvasoralen 1.2% Bath Lotion (8-methoxypsoralen)
Information supplied only on request from a healthcare professional by: CRAWFORD HEALTHCARE LTD Unit 1, Adams Court Adams Hill Knutsford Cheshire WA16 6BA PATIENT INFORMATION LEAFLET PUVA TREATMENT If
More informationMANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING
MANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING The Food, Drug & Cosmetics Act does not require that cosmetics be tested for safety. The U.S. Food and Drug Administration (FDA) does advise cosmetic
More informationNORMAL OCCURRENCES DURING TISSUE FILLER INJECTIONS, INCLUDING HYLAFORM and JUVEDERM
INSTRUCTIONS This informed-consent document has been prepared to help inform you about various soft tissue filler materials, their use, risks, and alternative treatments. It is important that you read
More informationCONSUMER MEDICINE INFORMATION
CONSUMER MEDICINE INFORMATION ACZONE (dapsone 7.5% w/w) topical gel January 2017 V 1.0 1 ACZONE gel (dapsone 7.5% w/w) Consumer Medicine Information What is in this leaflet This leaflet answers some common
More informationDP Fusidic Acid Cream
New Zealand Consumer Medicine Information DP Fusidic Acid Cream Fusidic Acid 20 mg/g (2 %) Cream What is in this leaflet Please read this leaflet carefully before you start using DP Fusidic Acid Cream.
More informationLUPIN LIMITED SAFETY DATA SHEET
LUPIN LIMITED SAFETY DATA SHEET Section 1: Identification Section 1, Identification Material Manufacturer Distributor Testosterone Topical Solution, 30 mg/1.5 ml Lupin Limited Pithampur (M.P.) 454 775
More informationINFORMATION ABOUT YOUR TREATMENT
INFORMATION ABOUT YOUR TREATMENT Indication OXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum,
More informationUniversity of Wisconsin-Madison Hazard Communication Standard Policy Dept. of Environment, Health & Safety Office of Chemical Safety
University of Wisconsin-Madison Hazard Communication Standard Policy Dept. of Environment, Health & Safety Office of Chemical Safety 1.0 Introduction... 1 1.1 Purpose... 1 1.2 Regulatory Background...
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 30-Apr-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product Name Product Type Recommended Use Uses advised against Synonyms 96858840_NA CoverGirlEyeEnhancersEyeshadow
More informationPRODUCT YES / NO BRAND NAME PRODUCT NAME FREQUENCY OF USE
Consultation Form Today s Date: Name: Your Birthday: Spouses Name: Spouses Birthday: Anniversary: Address: City: St: Zip Home Phone: Office Phone: Cell Phone: Email Address: Purpose for visit: How did
More informationMorningside College. Written Program. for. Hazard Communication
Morningside College Written Program for Hazard Communication 1910.1200 Hazard Communication Program Table of Contents I. Objective II. Assignment of Responsibility III. Program A. Hazardous Chemical List
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 30-Jun-2014 Version 1 1. PRODUCT AND COMPANY INFORMATION Product ID: Product Name Product Type Recommended Use Uses advised against 96959139_RET_NA DG Dolce Lipstick
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: 27-Feb-2013 Version 1 Product ID: 96334161 1. PRODUCT AND COMPANY IDENTIFICATION Product Name Product Type Recommended use Uses advised against Synonyms Manufacturer
More informationThe fight against infection starts at home.
The fight against infection starts at home. What is a surgical site infection? There are many microorganisms (germs) that live on our skin and in the environment around us. Very few of these microorganisms
More informationBAXTER ANNOUNCES U.S. FDA APPROVAL AND COMMERCIAL LAUNCH OF READY-TO-USE CLINDAMYCIN INJECTION IN SALINE
FOR IMMEDIATE RELEASE Media Contact Eric Tatro, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER ANNOUNCES U.S. FDA APPROVAL AND COMMERCIAL LAUNCH OF READY-TO-USE
More informationUnisooth EG-28 Rapid Control of Skin Irritation for the removal of Dark Circles
Unisooth EG-28 Rapid Control of Skin Irritation for the removal of Dark Circles The appearance of dark circles is a biologically complex process closely linked to subocular micro-inflammation. By actively
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Issuing Date: no data available Version 1 Product ID: Product Name Product Type Recommended use Uses advised against Synonyms Manufacturer E-mail Address Emergency telephone
More information